Cullinan Therapeutics, Inc.
NASDAQ: CGEM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Nadim Ahmed
- Employees
- 111
- Headquarters
- Cambridge, United States
- IPO year
- 2021
- Market cap
- $1.1B
- Website
- https://cullinantherapeutics.com
Loading CGEM…
Loading profile data…Frequently asked questions about CGEM
What does Cullinan Therapeutics, Inc. (CGEM) do?
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978,...
Where does CGEM trade?
Cullinan Therapeutics, Inc. (CGEM) trades on the NASDAQ Global Select.
What sector is CGEM in?
Cullinan Therapeutics, Inc. (CGEM) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Cullinan Therapeutics, Inc.?
Nadim Ahmed is the chief executive officer of Cullinan Therapeutics, Inc. (CGEM).
Where is Cullinan Therapeutics, Inc. headquartered?
Cullinan Therapeutics, Inc. is headquartered in United States.
Does CGEM pay a dividend?
Cullinan Therapeutics, Inc. (CGEM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CGEM go public?
Cullinan Therapeutics, Inc. (CGEM) completed its initial public offering in 2021.